To evaluate the efficacy and safety of disitamab vedotin (RC48) in the treatment of advanced gastric cancer in real-world settings.
Key Findings:
Objective response rate (ORR) was 10.3%; disease control rate (DCR) was 63.8%.
Median progression-free survival (mPFS) was 4.2 months, with a 1-year progression-free survival rate of 13.0%.
DCR was significantly higher in patients receiving RC48 as third-line therapy (75.0%) compared to later-line therapy (50.0%).
DCR was also higher in patients with adverse drug reactions (76.7%) than those without (50.0%).
Male patients had a longer mPFS (4.9 months) compared to female patients (2.6 months).
Common adverse drug reactions included neutropenia, hemoglobin reduction, and liver impairment, with 17.2% experiencing grade III or higher ADRs.
Interpretation:
Disitamab vedotin shows some clinical efficacy and a manageable safety profile in treating HER2-expressing advanced gastric cancer in a real-world setting, suggesting potential for broader application.
Limitations:
Retrospective study design may introduce bias, affecting the reliability of the results.
Single-center data may limit generalizability to a wider population.
Sample size of 58 patients may not be sufficient for broader conclusions, necessitating further studies.
Conclusion:
RC48 demonstrates potential clinical benefits and manageable safety in advanced gastric cancer, providing valuable insights for clinical practice and highlighting the need for further research.
